These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 6269771)
1. Zinostatin and doxorubicin. A combination phase I study. Issell BF; Ginsberg SJ; Comis RL Cancer Clin Trials; 1981; 4(3):323-6. PubMed ID: 6269771 [TBL] [Abstract][Full Text] [Related]
2. Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Schmidinger M; Wenzel C; Locker GJ; Muehlbacher F; Steininger R; Gnant M; Crevenna R; Budinsky AC Br J Cancer; 2001 Dec; 85(12):1850-2. PubMed ID: 11747325 [TBL] [Abstract][Full Text] [Related]
3. Neocarzinostatin: report of a phase II clinical trial. McKelvey EM; Murphy W; Zander A; Bodey GP Cancer Treat Rep; 1981; 65(7-8):699-701. PubMed ID: 6454486 [TBL] [Abstract][Full Text] [Related]
4. Phase I and preliminary phase II study of neocarzinostatin. Griffin TW; Comis RL; Lokich JJ; Blum RH; Canellos GP Cancer Treat Rep; 1978 Dec; 62(12):2019-25. PubMed ID: 221112 [TBL] [Abstract][Full Text] [Related]
5. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma. Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923 [TBL] [Abstract][Full Text] [Related]
6. Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma. Falkson G; MacIntyre JM; Schutt AJ; Coetzer B; Johnson LA; Simson IW; Douglass HO J Clin Oncol; 1984 Jun; 2(6):581-4. PubMed ID: 6327926 [TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin. Garcia AA; Roman L; Muderspach L; O'meara A; Facio G; Edwards S; Burnett A Cancer Invest; 2005; 23(8):665-70. PubMed ID: 16377584 [TBL] [Abstract][Full Text] [Related]
8. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days. Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122 [TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer. Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894 [TBL] [Abstract][Full Text] [Related]
10. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034 [TBL] [Abstract][Full Text] [Related]
11. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Giordano SH; Booser DJ; Murray JL; Ibrahim NK; Rahman ZU; Valero V; Theriault RL; Rosales MF; Rivera E; Frye D; Ewer M; Ordonez NG; Buzdar AU; Hortobagyi GN Clin Cancer Res; 2002 Nov; 8(11):3360-8. PubMed ID: 12429622 [TBL] [Abstract][Full Text] [Related]
12. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas. Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154 [TBL] [Abstract][Full Text] [Related]
13. Phase II clinical evaluation of 4'-epi-doxorubicin. Hurteloup P; Cappelaere P; Armand JP; Mathé G Cancer Treat Rep; 1983 Apr; 67(4):337-41. PubMed ID: 6573956 [TBL] [Abstract][Full Text] [Related]
15. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Söderdahl G; Bäckman L; Isoniemi H; Cahlin C; Höckerstedt K; Broomé U; Mäkisalo H; Friman S; Ericzon BG Transpl Int; 2006 Apr; 19(4):288-94. PubMed ID: 16573544 [TBL] [Abstract][Full Text] [Related]
16. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG). Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710 [TBL] [Abstract][Full Text] [Related]
17. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma. Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck. Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121 [TBL] [Abstract][Full Text] [Related]
19. [Repeated arterial infusion of zinostatin stimalamer using port for advanced hepatocellular carcinoma]. Yoshikawa M; Ebara M; Fukuda H; Sugiura N; Saisho H Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():30-3. PubMed ID: 9512684 [TBL] [Abstract][Full Text] [Related]
20. A comparative randomized trial of intermittent intrahepatic arterial carboplatin- versus doxorubicin-lipiodol emulsion in advanced hepatocellular carcinoma (stage IV). Homma H; Mezawa S; Doi T; Miyanishi K; Takada K; Kukitsu T; Oku T; Masuko E; Nojiri S; Niitsu Y Hepatogastroenterology; 2004; 51(58):1135-9. PubMed ID: 15239261 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]